Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery.

La-Beck NM, Liu X, Wood LM.

Front Pharmacol. 2019 Mar 12;10:220. doi: 10.3389/fphar.2019.00220. eCollection 2019.

2.

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.

Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkoungou S, Le AD, Wood LM, Gabizon AA, La-Beck NM.

J Control Release. 2018 Feb 10;271:139-148. doi: 10.1016/j.jconrel.2017.12.023. Epub 2017 Dec 23.

3.

Developing a Mass Casualty Surge Capacity Protocol for Emergency Medical Services to Use for Patient Distribution.

Shartar SE, Moore BL, Wood LM.

South Med J. 2017 Dec;110(12):792-795. doi: 10.14423/SMJ.0000000000000740.

PMID:
29197316
4.

TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.

Lowe DB, Bivens CK, Mobley AS, Herrera CE, McCormick AL, Wichner T, Sabnani MK, Wood LM, Weidanz JA.

MAbs. 2017 May/Jun;9(4):603-614. doi: 10.1080/19420862.2017.1302630.

5.

The Effects of Sympathetic Inhibition on Metabolic and Cardiopulmonary Responses to Exercise in Hypoxic Conditions.

Scalzo RL, Peltonen GL, Binns SE, Klochak AL, Szallar SE, Wood LM, Larson DG, Luckasen GJ, Irwin D, Schroeder T, Hamilton KL, Bell C.

Wilderness Environ Med. 2015 Dec;26(4):520-4. doi: 10.1016/j.wem.2015.04.004. Epub 2015 Jul 14.

PMID:
26183071
6.

Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.

Villarreal DO, Wise MC, Siefert RJ, Yan J, Wood LM, Weiner DB.

Mol Ther. 2015 Oct;23(10):1653-62. doi: 10.1038/mt.2015.120. Epub 2015 Jun 30.

7.

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses.

Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, Gabizon AA, La-Beck NM.

Nanomedicine. 2015 Feb;11(2):259-62. doi: 10.1016/j.nano.2014.08.010. Epub 2014 Sep 6.

PMID:
25200609
8.

Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Wood LM, Paterson Y.

Front Cell Infect Microbiol. 2014 May 12;4:51. doi: 10.3389/fcimb.2014.00051. eCollection 2014. Review.

9.

Regulators of human white adipose browning: evidence for sympathetic control and sexual dimorphic responses to sprint interval training.

Scalzo RL, Peltonen GL, Giordano GR, Binns SE, Klochak AL, Paris HL, Schweder MM, Szallar SE, Wood LM, Larson DG, Luckasen GJ, Hickey MS, Bell C.

PLoS One. 2014 Mar 6;9(6):e90696. doi: 10.1371/journal.pone.0090696. eCollection 2014.

10.

Greater muscle protein synthesis and mitochondrial biogenesis in males compared with females during sprint interval training.

Scalzo RL, Peltonen GL, Binns SE, Shankaran M, Giordano GR, Hartley DA, Klochak AL, Lonac MC, Paris HL, Szallar SE, Wood LM, Peelor FF 3rd, Holmes WE, Hellerstein MK, Bell C, Hamilton KL, Miller BF.

FASEB J. 2014 Jun;28(6):2705-14. doi: 10.1096/fj.13-246595. Epub 2014 Mar 5.

PMID:
24599968
11.

Total daily energy expenditure is increased following a single bout of sprint interval training.

Sevits KJ, Melanson EL, Swibas T, Binns SE, Klochak AL, Lonac MC, Peltonen GL, Scalzo RL, Schweder MM, Smith AM, Wood LM, Melby CL, Bell C.

Physiol Rep. 2013 Oct;1(5):e00131. doi: 10.1002/phy2.131. Epub 2013 Oct 24.

12.

Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis.

Hyland RM, Komlósi K, Alleman BW, Tolnai M, Wood LM, Bell EF, Ertl T.

Eur J Pediatr. 2013 Jun;172(6):803-9. doi: 10.1007/s00431-013-1966-y. Epub 2013 Feb 14.

13.

ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells.

Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S.

Exp Biol Med (Maywood). 2012 Jan;237(1):38-49. doi: 10.1258/ebm.2011.011236. Epub 2011 Dec 20.

PMID:
22185919
14.

The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.

Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y.

Cancer Immunol Immunother. 2012 May;61(5):689-700. doi: 10.1007/s00262-011-1129-9. Epub 2011 Nov 6.

15.

Toward a brief multidimensional assessment of emotional intelligence: psychometric properties of the Emotional Quotient Inventory-Short Form.

Parker JD, Keefer KV, Wood LM.

Psychol Assess. 2011 Sep;23(3):762-77. doi: 10.1037/a0023289.

PMID:
21500919
16.

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.

Cancer Immunol Immunother. 2011 Jul;60(7):931-42. doi: 10.1007/s00262-011-1002-x. Epub 2011 Mar 23.

17.

A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway.

Wood LM, Sankar S, Reed RE, Haas AL, Liu LF, McKinnon P, Desai SD.

PLoS One. 2011 Jan 26;6(1):e16422. doi: 10.1371/journal.pone.0016422.

18.

Can alexithymia be assessed in adolescents? Psychometric properties of the 20-item Toronto Alexithymia Scale in younger, middle, and older adolescents.

Parker JD, Eastabrook JM, Keefer KV, Wood LM.

Psychol Assess. 2010 Dec;22(4):798-808. doi: 10.1037/a0020256.

PMID:
20804260
19.

Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Paterson Y, Guirnalda PD, Wood LM.

Semin Immunol. 2010 Jun;22(3):183-9. doi: 10.1016/j.smim.2010.02.002. Epub 2010 Mar 17. Review.

20.

Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Wood LM, Pan ZK, Shahabi V, Paterson Y.

Cancer Immunol Immunother. 2010 Jul;59(7):1049-1058. doi: 10.1007/s00262-010-0830-4. Epub 2010 Mar 6.

21.

Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Wood LM, Guirnalda PD, Seavey MM, Paterson Y.

Immunol Res. 2008;42(1-3):233-45. doi: 10.1007/s12026-008-8087-0.

22.

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.

Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH.

Cancer Res. 2008 Aug 15;68(16):6669-79. doi: 10.1158/0008-5472.CAN-07-6627.

23.

ISG15 as a novel tumor biomarker for drug sensitivity.

Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF.

Mol Cancer Ther. 2008 Jun;7(6):1430-9. doi: 10.1158/1535-7163.MCT-07-2345.

24.

The impact of education and experience on death anxiety in new graduate nurses.

Brisley P, Wood LM.

Contemp Nurse. 2004 Jul-Aug;17(1-2):102-8.

PMID:
17929741
25.

G-quadruplexes induce apoptosis in tumor cells.

Qi H, Lin CP, Fu X, Wood LM, Liu AA, Tsai YC, Chen Y, Barbieri CM, Pilch DS, Liu LF.

Cancer Res. 2006 Dec 15;66(24):11808-16.

26.

A protease pathway for the repair of topoisomerase II-DNA covalent complexes.

Zhang A, Lyu YL, Lin CP, Zhou N, Azarova AM, Wood LM, Liu LF.

J Biol Chem. 2006 Nov 24;281(47):35997-6003. Epub 2006 Sep 13.

27.

Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

Baker KE, Wood LM, Whittaker M, Curtis MJ.

Br J Pharmacol. 2006 Oct;149(3):269-76. Epub 2006 Aug 21. Erratum in: Br J Pharmacol. 2006 Dec;149(7):966.

28.

Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway.

Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur-E-Kamal A, Liu LF.

Cancer Res. 2006 Jan 15;66(2):921-8.

29.

Use of the Conners-wells adolescent self-report scale (short form) with children.

Parker JD, Bond BJ, Reker DL, Wood LM.

J Atten Disord. 2005 May;8(4):188-94.

PMID:
16110049
30.

Cross-cultural alexithymia: validity of the 20-item Toronto Alexithymia Scale in North American aboriginal populations.

Parker JD, Shaughnessy PA, Wood LM, Majeski SA, Eastabrook JM.

J Psychosom Res. 2005 Jan;58(1):83-8.

PMID:
15771874
31.

Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen.

Comer MB, Cackett KS, Gladwell S, Wood LM, Dawson KM.

J Thromb Haemost. 2005 Jan;3(1):146-53.

32.

Alexithymia in young adulthood: a risk factor for pathological gambling.

Parker JD, Wood LM, Bond BJ, Shaughnessy P.

Psychother Psychosom. 2005;74(1):51-5.

PMID:
15627857
33.

A beam-splitting device for use with fiber-coupled laser light sources for photodynamic therapy.

Wood LM, Bellnier DA, Oseroff AR, Potter WR.

Photochem Photobiol. 2002 Dec;76(6):683-5.

PMID:
12511051
34.

The role of nursing unit managers in educating nurses.

Duffield C, Wood LM, Franks H, Brisley P.

Contemp Nurse. 2001 Jun;10(3-4):244-50.

PMID:
11855119
35.
36.

Design and construction of a light-delivery system for photodynamic therapy.

Bellnier DA, Wood LM, Potter WR, Weishaupt KR, Oseroff AR.

Med Phys. 1999 Aug;26(8):1552-8.

PMID:
10501055
37.

Preclinical and clinical studies of MMP inhibitors in cancer.

Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A.

Ann N Y Acad Sci. 1999 Jun 30;878:228-35. Review.

PMID:
10415734
38.

Clinical and cost effectiveness of post-acute neurobehavioural rehabilitation.

Wood RL, McCrea JD, Wood LM, Merriman RN.

Brain Inj. 1999 Feb;13(2):69-88.

PMID:
10079953
39.

Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.

Marshall E, Howell AH, Powles R, Hunter MG, Edwards M, Wood LM, Czaplewski L, Puttick R, Warrington S, Boyce M, Testa N, Dexter TM, Lord BI, Millar A.

Eur J Cancer. 1998 Jun;34(7):1023-9.

PMID:
9849450
40.

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.

Clemons MJ, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Earl H, Kiernan J, Griffiths A, Towlson K, DeTakats P, Testa NG, Dougal M, Hunter MG, Wood LM, Czaplewski LG, Millar A, Dexter TM, Lord BI.

Blood. 1998 Sep 1;92(5):1532-40.

PMID:
9716580
41.

Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.

Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJ, Miller KM.

J Neuroimmunol. 1997 Apr;74(1-2):85-94.

PMID:
9119983
42.

Sensitivity and specificity of QEEG in children with attention deficit or specific developmental learning disorders.

Chabot RJ, Merkin H, Wood LM, Davenport TL, Serfontein G.

Clin Electroencephalogr. 1996 Jan;27(1):26-34.

PMID:
8719499
43.
44.

BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.

Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ.

Blood. 1995 Dec 15;86(12):4400-8.

PMID:
8541527
45.

Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.

Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM.

Blood. 1995 Jun 15;85(12):3412-5.

PMID:
7540061
46.

Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist.

Formela LJ, Wood LM, Whittaker M, Kingsnorth AN.

Br J Surg. 1994 Dec;81(12):1783-5.

PMID:
7827939
47.
48.

Reliability of labial closure force measurements in normal subjects and patients with CNS disorders.

Wood LM, Hughes J, Hayes KC, Wolfe DL.

J Speech Hear Res. 1992 Apr;35(2):252-8.

PMID:
1573865
50.

Supplemental Content

Support Center